Fulcrum Therapeutics, Inc. (FULC)
Largest Insider Buys in Sector
FULC Stock Price History Chart
FULC Stock Performance
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug …
Insider Activity of Fulcrum Therapeutics, Inc.
Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $492,028 and sold $59,050 worth of Fulcrum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $13.54M and sold $1.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sapir Alex (See Remarks) — $492,028.
The last purchase of 43,360 shares for transaction amount of $492,028 was made by Sapir Alex (See Remarks) on 2024‑03‑04.
List of Insider Buy and Sell Transactions, Fulcrum Therapeutics, Inc.
| 2024-05-07 | Sale | Principal Accounting Officer | 236 0.0004% | $7.76 | $1,831 | +0.13% | ||
| 2024-03-08 | Sale | Vice President, Finance | 4,884 0.0084% | $11.72 | $57,219 | -30.51% | ||
| 2024-03-04 | See Remarks | 43,360 0.0707% | $11.35 | $492,028 | -31.88% | |||
| 2023-05-10 | Sale | Principal Accounting Officer | 210 0.0004% | $3.31 | $695 | +46.79% | ||
| 2023-01-20 | director | 1.92M 3.8009% | $13.00 | $25M | -68.65% | |||
| 2023-01-13 | Sale | Interim President & CEO | 6,766 0.0142% | $15.00 | $101,490 | -71.09% | ||
| 2023-01-04 | director | 180,703 0.3049% | $7.28 | $1.31M | -52.11% | |||
| 2022-12-27 | director | 4,089 0.009% | $5.99 | $24,510 | -34.35% | |||
| 2022-12-19 | director | 98,787 0.2145% | $5.90 | $582,814 | -34.35% | |||
| 2022-12-16 | director | 1.34M 3.0203% | $5.42 | $7.27M | -25.98% | |||
| 2022-12-15 | director | 237,029 0.5283% | $5.50 | $1.3M | -27.65% | |||
| 2022-12-14 | director | 824,600 1.8392% | $5.46 | $4.5M | -27.11% | |||
| 2022-06-07 | Sale | 71,435 0.1753% | $8.09 | $577,895 | -23.70% | |||
| 2022-06-02 | Sale | 16,689 0.043% | $7.92 | $132,162 | -16.89% | |||
| 2022-04-07 | Sale | 5,631 0.0145% | $24.02 | $135,228 | -68.29% | |||
| 2022-04-01 | Sale | 52,552 0.1313% | $24.26 | $1.27M | -69.08% | |||
| 2021-08-11 | Sale | See Remarks | 28,000 0.0899% | $23.75 | $665,000 | -25.57% | ||
| 2021-08-10 | Sale | See Remarks | 32,000 0.0815% | $17.50 | $560,000 | -19.71% | ||
| 2021-08-10 | Sale | Chief Scientific Officer | 51,785 0.1326% | $17.60 | $911,416 | -19.71% | ||
| 2021-06-28 | director | 10,000 0.0312% | $9.16 | $91,600 | +68.04% |
Insider Historical Profitability
| Sapir Alex | See Remarks | 43360 0.0804% | $2.98 | 1 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | director | 11609704 21.5239% | $2.98 | 7 | 0 | <0.0001% |
| LEVIN MARK J | 5962202 11.0537% | $2.98 | 1 | 0 | +2.11% | |
| Third Rock Ventures III, L.P. | 10 percent owner | 5962202 11.0537% | $2.98 | 1 | 0 | +2.11% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 2343154 4.3441% | $2.98 | 1 | 0 | +2.11% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $109.6M | 18.68 | 11.61M | 0% | +$0 | 0.11 | |
| RTW Investments, LP | $55.19M | 9.41 | 5.85M | +6.87% | +$3.55M | 0.83 | |
| Fidelity Investments | $50.64M | 8.63 | 5.36M | -5.63% | -$3.02M | <0.01 | |
| Cowen Group | $35.06M | 5.98 | 3.71M | +6.91% | +$2.27M | 1.12 | |
| Suvretta Capital Management, LLC | $26.89M | 4.58 | 2.85M | -48.39% | -$25.21M | 1.14 |